Data

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

Retrieved on: 
Friday, April 5, 2024
Retina, Disease, Inflammation, Patient, Data, Cohort, Șaeș, Life, Clinical trial, Armada, MPH, Injection, Safety, DSMB, FACS, Vaccine, Lipid metabolism, Geographic atrophy, Oxidative stress, Pharmaceutical industry

Three subjects with geographic atrophy (GA) were dosed in the Phase 1/2 clinical trial to date.

Key Points: 
  • Three subjects with geographic atrophy (GA) were dosed in the Phase 1/2 clinical trial to date.
  • An additional three subjects will be dosed with the medium dose (Cohort 2) and three patients with the high dose (Cohort 3) of OCU410 in the dose-escalation phase.
  • “The DSMB has recommended moving forward to medium dose for dosing subjects with GA,” said Dr. Peter Chang, MD, FACS, DSMB Chair for the OCU410 clinical trial.
  • Phase 1 is a multicenter, open-label, dose-ranging study consisting of three dose levels [low dose (2.5×1010 vg/mL), medium dose (5×1010 vg/mL), and high dose (1.5 ×1011 vg/mL)].

SNOW Litigation Report: Levi & Korsinsky, LLP Provides Investors Further Information on Lawsuit Against Snowflake Inc.

Retrieved on: 
Friday, April 5, 2024
Organization, Growth, Data science, District court, United States district court, Snowflake Inc., LLP, SNOW, Court, Data, Prospectus

They are now seeking compensation for financial losses incurred upon public revelation of the Company’s alleged misconduct during that time.

Key Points: 
  • They are now seeking compensation for financial losses incurred upon public revelation of the Company’s alleged misconduct during that time.
  • Snowflake (NYSE:SNOW) engages in the provision of a data cloud platform.
  • Specifically, they are accused of omitting truthful information about the Company’s growth and revenue from SEC filings and related material.
  • By knowingly or recklessly doing so, they allegedly caused Snowflake stock to trade at artificially inflated prices during the time in question.

Gretel Releases World’s Largest Open Source Text-to-SQL Dataset to Accelerate AI Model Training

Retrieved on: 
Thursday, April 4, 2024
Blood pressure, Hugging Face, SQL, Spider, Yale University, MIT, Patient, SAN, Head, Ageing, Blog, AI, Student, LLM, Statistics, Clinical trial, Language, Data, Metadata, Population growth, Mobile phone

SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Gretel , the leader in synthetic data, today released the world’s largest open source Text-to-SQL dataset to unlock new possibilities for AI in the enterprise.

Key Points: 
  • SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Gretel , the leader in synthetic data, today released the world’s largest open source Text-to-SQL dataset to unlock new possibilities for AI in the enterprise.
  • "Access to quality training data is one of the biggest obstacles to building with generative AI.
  • Everything Gretel does is designed to address this issue head-on, and contributing to the open-source community is no exception," said Alex Watson, co-founder & Chief Product Officer at Gretel.
  • We’re excited for developers to take our dataset for a spin, and build upon it.”
    The largest AI companies in the world are struggling with access to high-quality training data.

HEALWELL AI’s Pentavere Achieves Validation of Generative AI for Preventative Care Through Landmark Publication

Retrieved on: 
Thursday, April 4, 2024
Princess Margaret Cancer Centre, Lung cancer, Data science, Real, Patient, Research, Cancer, AI, Oncology, TSX, Language, Data, Artificial intelligence, Health, AIDX, Medical device

Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using LLMs for preventative care purposes puts HEALWELL in a select group of companies globally with such capabilities.

Key Points: 
  • Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using LLMs for preventative care purposes puts HEALWELL in a select group of companies globally with such capabilities.
  • TORONTO, April 04, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is pleased to announce its subsidiary Pentavere Research Group (“Pentavere”) has achieved a significant milestone with the publication of a paper validating the use of generative AI to identify rare lung cancer patients.
  • We’ve developed best in class AI that is core to our mission of preventative care.
  • This milestone validates the power of fine-tuned generative AI to drive meaningful insights and transform patient care.

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
Thursday, April 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

Brainlab and Fujifilm Integrate Cutting-Edge Technology, Offering Advanced Capabilities to Neurosurgery Clinicians in the U.S.

Retrieved on: 
Thursday, April 4, 2024
Element, MRI, Surgeon, Brain, Digital, Patient, Brainlab, Neurosurgery, Neoplasm, Imri, Data, FDA, Health, Medical imaging

ARIETTA Precision , in conjunction with a Brainlab surgical navigation system , becomes a powerful intraoperative neurosurgery solution, delivering advanced guidance and image quality for critical surgical decisions.

Key Points: 
  • ARIETTA Precision , in conjunction with a Brainlab surgical navigation system , becomes a powerful intraoperative neurosurgery solution, delivering advanced guidance and image quality for critical surgical decisions.
  • Together, the systems serve as a deeply integrated end-to-end solution providing comprehensive intraoperative information leveraging the best of both worlds in imaging and navigation.
  • This combined solution is expected to be FDA cleared and available in the United States in mid-2024.
  • * The combination of these technologies provides neurosurgeons with real-time insights through live intraoperative ultrasound (IOUS) during neurosurgical procedures.

Accelerated Computing Leader Voltron Data Named to the CB Insights AI 100 for Being the One of Most Promising AI Companies in the World

Retrieved on: 
Wednesday, April 3, 2024
Organization, Government, Data, GPU, Memory, Theseus, Lightning, SAN, CB Insights, Research, AI, Graphics processing unit, NVIDIA, HPE

SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Voltron Data , the company accelerating modular and composable data analytics systems, today announced that it has been named to the CB Insights AI 100 that showcases the 100 most promising private AI companies of 2024.

Key Points: 
  • SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Voltron Data , the company accelerating modular and composable data analytics systems, today announced that it has been named to the CB Insights AI 100 that showcases the 100 most promising private AI companies of 2024.
  • Voltron Data is the only company honored in the accelerated computing category: https://www.cbinsights.com/learn/ai-100-2024 .
  • “AI is taking off at lightning speed, and it’s not just big tech companies at the forefront of it,” said Deepashri Varadharajan, director of AI research at CB Insights.
  • “GPUs are ideal for the whole data pipeline, not just computationally hard things such as AI/ML,” said Josh Patterson, co-founder and CEO of Voltron Data.

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

Retrieved on: 
Tuesday, April 2, 2024
Stargardt disease, Disease, Safety, Webcast, Inflammation, Patient, CGMP, Data, Inhalation, Cohort, RP, Life, Bank statement, Investment, Clinical trial, NIAID, Injection, AMD, Vaccine, Nextgen, Geographic atrophy, RHO, FDA, Lipid metabolism, Government, Oxidative stress, Pharmaceutical industry

Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively

Key Points: 
  • Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively
    MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today provided a general business update with certain financials for the year ending 2023.
  • During the fourth quarter of 2023, the Company announced its mucosal vaccine candidate, OCU500, was chosen for the multi-billion-dollar NIAID Project NextGen initiative.
  • The first patient was dosed in the Phase 1/2 trials to assess the safety and efficacy of OCU410ST for Stargardt disease in November 2023.
  • Ocugen’s cash, cash equivalents, and investments totaled $39.5 million as of December 31, 2023, compared to $90.9 million as of December 31, 2022.

Sift Surges to #1 Position in Spring 2024 G2 Reports in Fraud Detection and Risk-Based Authentication Categories

Retrieved on: 
Tuesday, April 2, 2024
Algorithm, MFA, Face, Learning, E-commerce, Sieve, SAN, Research, IP, Fraud, Geography, Machine learning, Data, G2, Online shopping

In the report, Sift holds the top score in Fraud Detection and Risk-Based Authentication and is also a Leader in E-Commerce Fraud Detection.

Key Points: 
  • In the report, Sift holds the top score in Fraud Detection and Risk-Based Authentication and is also a Leader in E-Commerce Fraud Detection.
  • This is Sift’s 12th consecutive quarter for being named G2 Leader in Fraud Detection, 17th consecutive quarter for E-Commerce, and 6th consecutive quarter for Risk-Based Authentication.
  • Sift is the only company to be named a Leader in all three fraud prevention categories.
  • In the new Spring update, Sift also ranked number one in 18 reports, earning 21 leader badges.

Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease

Retrieved on: 
Tuesday, April 2, 2024
UKB, Health, Kingdom of Poland, Prostate cancer, Chronic lymphocytic leukemia, CLL, Disease, Partnership, Risk, Biomarker, Research, FCRL2, Protein, Biology, Medicine, Biobank, Data, UK Biobank, Pharmaceutical industry

In April 2023, the UK Biobank Pharma Proteomics Project (UKB-PPP) released data produced from over 50,000 samples analyzed using the Olink® Explore platform.

Key Points: 
  • In April 2023, the UK Biobank Pharma Proteomics Project (UKB-PPP) released data produced from over 50,000 samples analyzed using the Olink® Explore platform.
  • The UKB-PPP is the largest population-scale proteomics study to date, yielding an unprecedented view into the biology of diseased and healthy individuals over a 10-year period.
  • By combining protein measurements with longitudinal healthcare data for each of the individuals, Olink derived the estimated effects of ~3,000 proteins on the future risk of disease.
  • Olink Insight is a free, web-based platform that puts the results of advanced computational data analysis into the hands of non-data scientists.